Triclabendazole Powder

In the mid-20th century, liver fluke disease (caused by liver flukes) was widely spread in animal husbandry, resulting in slow growth, decreased milk production, and even death in ruminant animals such as cattle and sheep, causing huge economic losses to global animal husbandry. At the same time, although cases of human infection with liver flukes are rare, the misdiagnosis rate is high, treatment is difficult, and efficient drugs are urgently needed. At that time, traditional deworming drugs such as praziquantel and albendazole had limited effectiveness against liver flukes and had resistance issues, prompting scientists to search for new antiparasitic compounds.

1. Wide application in animal husbandry

In the late 1980s, Triclabendazole was officially approved for clinical use in ruminant livestock including cattle and sheep, and has gradually become the gold-standard and preferred therapeutic drug for animal liver fluke disease worldwide. It targets both adult and immature liver flukes, covering the whole parasitic stage of the pathogen, which endows it with incomparable advantages over traditional anthelmintics. Its core strengths are summarized as follows:

Efficiency: A single oral dose of 10–12 mg/kg can achieve a deworming efficacy of over 95%, effectively eliminating internal parasites and reducing livestock mortality and growth retardation caused by fluke infection;

Safety: It exhibits extremely low host toxicity with mild and rare adverse reactions, and is safe for special livestock groups including pregnant animals, lactating individuals and young growing animals, with no obvious teratogenic or developmental toxic effects;

Convenience: The active pharmaceutical ingredient possesses excellent chemical stability under conventional storage and breeding conditions. It can be processed into diverse dosage forms such as tablets, granules and oral suspensions, adapting to different feeding modes and facilitating large-scale administration in modern intensive breeding farms.

Driven by the rapid expansion of global intensive animal husbandry and the increasing prevalence of livestock fluke diseases, the market demand for triclabendazole has maintained steady growth, with annual global market sales exceeding hundreds of millions of US dollars.

2. Breakthrough applications in human medicine

In 1988, British clinicians pioneered the off-label use of triclabendazole for the treatment of two human fascioliasis cases, achieving remarkable curative effects and filling the clinical gap for refractory human liver fluke infection treatment. Subsequent clinical trials and practical verification further expanded its human medical indications, covering paragonimiasis (lung fluke disease) and other zoonotic trematode infections.

Notably, triclabendazole shows prominent therapeutic superiority in clinical cases with drug resistance to the first-line drug praziquantel, serving as a critical alternative rescue medication. Recognizing its high efficacy and safety in human parasitic disease treatment, the World Health Organization (WHO) has formally listed triclabendazole as a core recommended drug for Fasciola hepatica infection. It is widely promoted and applied in fluke-endemic regions such as Africa, South America and parts of Asia, becoming an essential pharmaceutical tool for global parasitic disease prevention and control.